

## News Release

### Media contact:

Teresa Pavlin  
Office: (416) 382-5017  
Mobile: (647) 638-5908

### **Prince Edward Island drug plan now includes REMICADE® for the treatment of multiple autoimmune diseases**

*Agreement assures new and existing patients have access to their treatment of choice*

**TORONTO, ON, March 27, 2018** – The Janssen Pharmaceutical Companies of Johnson & Johnson announce the completion of an important agreement for public reimbursement of REMICADE® (infliximab) with the government of Prince Edward Island, effective February 15, 2018. This agreement, sets the cost of REMICADE® at the same level as other treatment options, including biosimilars and assures patients continued access and continuity of infusion services through the network of clinics across the province.

REMICADE®, a biologic treatment, will be considered as an option for new REMICADE® patients, as well as those patients on maintenance therapy, if criteria is met for the following conditions as identified in the [PEI Pharmacare Formulary](#): ankylosing spondylitis, Crohn’s disease, plaque psoriasis, psoriatic arthritis and rheumatoid arthritis.

“Treatment decisions should exclusively lie with physicians and their patients, so we are pleased that patients in PEI have the support of their government with this agreement to continue or start REMICADE®,” says Julia Brown, Vice President, Access, Janssen.

Janssen values the collaborative approach demonstrated through this listing agreement. As a company committed to patient care, Janssen commends the government of Prince Edward Island for their ongoing commitment to providing patients with a choice of cost-effective medications. Janssen looks forward to continued collaboration with provincial and territorial drug plans to ensure health system sustainability and access to a wide range of treatment options for all Canadian patients and physicians.

As a market leader and pioneer in biologics, Janssen is dedicated to improving the lives of Canadians by bringing new and innovative medicines to Canada. Restrictions on choice for new medicines limits access for patients and physicians to much needed innovative options now and in the future.

Janssen remains committed to ensuring patients have affordable access to the innovative medicines they need.

### **About the Janssen Pharmaceutical Companies of Johnson & Johnson**

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.

We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at [www.janssen.com/canada](http://www.janssen.com/canada). Follow us on Twitter [@JanssenCanada](https://twitter.com/JanssenCanada). Janssen Inc. is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

# # #